NW Bio appoints vet Rosskamp as CEO of German subsidiary
Friday, September 21, 2012
Northwest Biotherapeutics, a biotech developing DCVaxR personalized immune therapies for cancer, has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the company’s German subsidiary, Northwest Biotherapeutics, Gmbh.
Rosskamp brings extensive experience as a senior manager in the pharmaceutical sector. He previously served as head of central nervous system (CNS) therapeutics at Schering (now part of Bayer) with responsibility for R&D and global marketing and sales of CNS products. He subsequently served as head of strategic business development at Schering, Rosskamp also served as vice president of life sciences and chemicals at the German Industrial Investment Council (IIC). More recently, he served as CEO of three biotech companies, including a company developing treatments for inflammatory and immune disorders, and two companies developing cell therapy products.
Rosskamp succeeds Dr. Bernhard Faber, who served as the interim start-up CEO of Northwest Biotherapeutics’ German subsidiary.